Magnesium Trisilicate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Magnesium Trisilicate: From Antacid Use to Active Peptic Ulcer Disease
One-Sentence Summary
Magnesium trisilicate is a classic antacid, traditionally used for symptomatic relief of dyspepsia and acid-related gastrointestinal discomfort. The TxGNN model predicts it may be effective for Active Peptic Ulcer Disease, with no registered clinical trials and 4 historical publications (1970–1986) providing indirect supporting evidence. The drug is not currently registered on Australia’s ARTG.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this Evidence Pack; internationally known as an antacid for dyspepsia/heartburn |
| Predicted New Indication | Active Peptic Ulcer Disease |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L4 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this drug in the Evidence Pack. Based on general pharmacological knowledge, magnesium trisilicate belongs to the antacid drug class; its acid-neutralising effect is well established for symptomatic relief of acid-related gastrointestinal complaints, and mechanistically this same acid-neutralising action may be applicable to active peptic ulcer disease.
Both conditions share a common pathophysiological target: excess gastric acid and pepsin activity that irritate or prevent healing of the gastric/duodenal mucosa. Historically, magnesium trisilicate (often in combination with aluminium hydroxide or as a comparator/placebo constituent) has appeared in peptic ulcer research — for example, it was used as the placebo comparator in a 1970 duodenal ulcer trial (PMID 4909818), suggesting a long-recognised, if informal, role in ulcer management contexts.
Mechanistically, magnesium trisilicate neutralises gastric acid and can form a protective silica-gel layer over the mucosa, which is consistent with standard antacid therapy for active peptic ulcers. However, the supporting literature identified here is largely historical (pre-1990), indirect (studies of related antacids/alginates rather than magnesium trisilicate specifically), and no modern registered clinical trials directly test this compound for this indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 2986275 | 1985 | Cohort | Scandinavian Journal of Gastroenterology | Compared sucralfate vs. an alginate/antacid compound in reflux esophagitis; both groups showed significant symptomatic improvement (~70%), with esophagitis healing in 53% on sucralfate |
| 4909818 | 1970 | Cohort | Gut | Double-blind trial of Duogastrone for active duodenal ulcers; control group received a placebo containing magnesium trisilicate |
| 2877526 | 1986 | Review | Zeitschrift für Gastroenterologie | Reviews GERD therapy stepwise approach, placing antacid/alginate combinations as first-line (Phase I) treatment |
| 432256 | 1979 | Other | Die Pharmazie | Found that adsorbent antacid/peptic-ulcer drugs significantly reduced dissolution of norethisterone acetate from oral contraceptive tablets (drug-interaction relevance, not efficacy) |
Safety Considerations
Please refer to the source-market Product Information (PI) for magnesium trisilicate for safety information — this drug does not currently have a TGA-approved PI, as it is not registered on Australia’s ARTG. No TGA/TFDA-specific warnings, contraindications, or drug interaction data are currently available in this Evidence Pack (marked as a Blocking data gap for safety review).
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for magnesium trisilicate specifically in active peptic ulcer disease is limited to indirect, historical (pre-1990) literature with no direct clinical trials, and the drug is not registered in Australia. A Blocking data gap (missing PI warnings/contraindications) prevents even a preliminary safety assessment (S1).
To proceed, the following is needed:
- Source-market Product Information (PI) with warnings and contraindications, to clear the Blocking data gap
- Mechanism of action (MOA) data from DrugBank or equivalent source
- Direct clinical evidence (trials or contemporary studies) evaluating magnesium trisilicate specifically — rather than related antacids — in active peptic ulcer disease
- A regulatory pathway assessment, since the drug currently holds no ARTG registration in Australia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.